B O Taiwo

Summary

Affiliation: Northwestern University
Country: USA

Publications

  1. ncbi request reprint Primary human immunodeficiency virus
    Babafemi O Taiwo
    Early Intervention Clinic, Lincoln Health Center, Durham, NC 27707, USA
    South Med J 95:1312-7. 2002
  2. ncbi request reprint Evidence for risk stratification when monitoring for toxicities following initiation of combination antiretroviral therapy
    Babafemi Taiwo
    Infectious Diseases Division, Northwestern University, Chicago, IL 60611, USA
    AIDS 27:1593-602. 2013
  3. pmc Associations of T cell activation and inflammatory biomarkers with virological response to darunavir/ritonavir plus raltegravir therapy
    Babafemi Taiwo
    Division of Infectious Diseases, Northwestern University, Chicago, IL 60611, USA
    J Antimicrob Chemother 68:1857-61. 2013
  4. pmc CD8+ T-cell activation in HIV-1-infected patients experiencing transient low-level viremia during antiretroviral therapy
    Babafemi Taiwo
    Division of Infectious Diseases, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    J Acquir Immune Defic Syndr 63:101-4. 2013
  5. doi request reprint Understanding and controlling chronic immune activation in the HIV-infected patients suppressed on combination antiretroviral therapy
    Babafemi Taiwo
    Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, 645 North Michigan Avenue, Suite 900, Chicago, IL 60611, USA
    Curr HIV/AIDS Rep 10:21-32. 2013
  6. ncbi request reprint Suboptimal etravirine activity is common during failure of nevirapine-based combination antiretroviral therapy in a cohort infected with non-B subtype HIV-1
    Babafemi Taiwo
    Northwestern University Feinberg School of Medicine, Infectious Diseases Division, Chicago, IL 60611, USA
    Curr HIV Res 8:194-8. 2010
  7. doi request reprint Unmet therapeutic needs in the new era of combination antiretroviral therapy for HIV-1
    Babafemi Taiwo
    Division of Infectious Diseases, Department of Medicine, Northwestern University Medical School, Chicago, IL, USA
    J Antimicrob Chemother 65:1100-7. 2010
  8. doi request reprint Nontuberculous mycobacterial lung diseases
    Babafemi Taiwo
    Division of Infectious Diseases, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Infect Dis Clin North Am 24:769-89. 2010
  9. pmc Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy
    Babafemi Taiwo
    Division of Infectious Diseases, Northwestern University, Chicago, Illinois 60611, USA
    J Infect Dis 204:515-20. 2011
  10. pmc Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262)
    Babafemi Taiwo
    Division of Infectious Diseases, Northwestern University, Chicago, Illinois 60611, USA
    AIDS 25:2113-22. 2011

Detail Information

Publications21

  1. ncbi request reprint Primary human immunodeficiency virus
    Babafemi O Taiwo
    Early Intervention Clinic, Lincoln Health Center, Durham, NC 27707, USA
    South Med J 95:1312-7. 2002
    ..The current approach to management of primary HIV infection is based more on expert opinion than clinical trial results, though ongoing clinical trials should provide more information about this syndrome...
  2. ncbi request reprint Evidence for risk stratification when monitoring for toxicities following initiation of combination antiretroviral therapy
    Babafemi Taiwo
    Infectious Diseases Division, Northwestern University, Chicago, IL 60611, USA
    AIDS 27:1593-602. 2013
    ..We assessed laboratory abnormalities during initial cART in 2000-2010 across the United States...
  3. pmc Associations of T cell activation and inflammatory biomarkers with virological response to darunavir/ritonavir plus raltegravir therapy
    Babafemi Taiwo
    Division of Infectious Diseases, Northwestern University, Chicago, IL 60611, USA
    J Antimicrob Chemother 68:1857-61. 2013
    ..We also evaluated associations between these biomarkers and the virological response to the regimen...
  4. pmc CD8+ T-cell activation in HIV-1-infected patients experiencing transient low-level viremia during antiretroviral therapy
    Babafemi Taiwo
    Division of Infectious Diseases, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    J Acquir Immune Defic Syndr 63:101-4. 2013
    ..We found that TLLV does not significantly change CD8 T-cell activation and that higher CD8 T-cell activation during viral suppression <50 copies per milliliter is associated with a modest increase in the risk of a subsequent TLLV...
  5. doi request reprint Understanding and controlling chronic immune activation in the HIV-infected patients suppressed on combination antiretroviral therapy
    Babafemi Taiwo
    Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, 645 North Michigan Avenue, Suite 900, Chicago, IL 60611, USA
    Curr HIV/AIDS Rep 10:21-32. 2013
    ..Although several interventions have shown promise in vitro or in preliminary clinical trials, no intervention has sufficient evidence for routine use, making control of immune activation during cART an unmet need...
  6. ncbi request reprint Suboptimal etravirine activity is common during failure of nevirapine-based combination antiretroviral therapy in a cohort infected with non-B subtype HIV-1
    Babafemi Taiwo
    Northwestern University Feinberg School of Medicine, Infectious Diseases Division, Chicago, IL 60611, USA
    Curr HIV Res 8:194-8. 2010
    ..The primary objective of this study was to estimate etravirine activity in a cohort of patients infected with non-B subtype HIV-1 and failing nevirapine-based therapy...
  7. doi request reprint Unmet therapeutic needs in the new era of combination antiretroviral therapy for HIV-1
    Babafemi Taiwo
    Division of Infectious Diseases, Department of Medicine, Northwestern University Medical School, Chicago, IL, USA
    J Antimicrob Chemother 65:1100-7. 2010
    ..HIV also affects immune system senescence and bone turnover. This review discusses potential unmet needs with respect to these issues...
  8. doi request reprint Nontuberculous mycobacterial lung diseases
    Babafemi Taiwo
    Division of Infectious Diseases, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Infect Dis Clin North Am 24:769-89. 2010
    ..NTM species have different antibiotic response patterns, and success with medical treatment alone varies. Macrolides are an essential component of therapy for many species but must be combined with other drugs...
  9. pmc Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy
    Babafemi Taiwo
    Division of Infectious Diseases, Northwestern University, Chicago, Illinois 60611, USA
    J Infect Dis 204:515-20. 2011
    ..The most common mutations were M184I/V (14 cases), K103N (9), and M230L (3). Detection of new mutations was associated with higher HIV-1 RNA levels during persistent low-level viremia...
  10. pmc Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262)
    Babafemi Taiwo
    Division of Infectious Diseases, Northwestern University, Chicago, Illinois 60611, USA
    AIDS 25:2113-22. 2011
    ..To explore darunavir/ritonavir (DRV/r) plus raltegravir (RAL) combination therapy in antiretroviral-naive patients...
  11. doi request reprint Adherence to antiretroviral therapy: the more you look, the more you see
    Babafemi Taiwo
    Infectious Diseases Division, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60045, USA
    Curr Opin HIV AIDS 4:488-92. 2009
    ..The present review aims to discuss recent research findings that illuminate lingering clinical questions or contribute to the contextual framework for future research...
  12. pmc Higher risk of AIDS or death in patients with lower CD4 cell counts after virally suppressive HAART
    B O Taiwo
    Division of Infectious Diseases, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    HIV Med 10:657-60. 2009
    ..The clinical implications of a failure to achieve high CD4 cell counts while receiving virally suppressive highly active antiretroviral therapy (HAART) are uncertain...
  13. ncbi request reprint Nevirapine toxicity
    B O Taiwo
    Division of Infectious Diseases, Northwestern University Medical School, Chicago, IL 60611, USA
    Int J STD AIDS 17:364-9; quiz 370. 2006
    ....
  14. ncbi request reprint Man with a right thigh mass
    Babafemi O Taiwo
    Department of Infectious Diseases, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Clin Infect Dis 44:417, 462-3. 2007
  15. ncbi request reprint Can tumor necrosis factor alpha blockade predispose to severe babesiosis?
    Babafemi Taiwo
    Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA
    Arthritis Rheum 57:179-81. 2007
  16. ncbi request reprint Transmitted Resistance: An Overview and Its Potential Relevance to the Management of HIV-Infected Persons in Resource-Limited Settings
    Babafemi O Taiwo
    Division of Infectious Diseases at Northwestern University Feinberg School of Medicine, Chicago, IL
    J Int Assoc Physicians AIDS Care (Chic) 6:188-97. 2007
    ..Equally germane are epidemiological and clinical studies to extend understanding of the dynamics, clinical implications, and management of transmitted resistance...
  17. ncbi request reprint Clinical applications and availability of CD4+ T cell count testing in sub-Saharan Africa
    Babafemi O Taiwo
    Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
    Cytometry B Clin Cytom 74:S11-8. 2008
    ....
  18. doi request reprint Understanding transmitted HIV resistance through the experience in the USA
    Babafemi Taiwo
    Northwestern University, 645 North Michigan Av, Lake Forest, Illinois, USA
    Int J Infect Dis 13:552-9. 2009
    ..It appears transmitted drug resistance is still relatively low in developing countries, but there is a dearth of information...
  19. doi request reprint Assessing the viorologic and adherence benefits of patient-selected HIV treatment partners in a resource-limited setting
    Babafemi O Taiwo
    Division of Infectious Diseases, Feinberg School of Medicine, Northwestern University, 645 N Michigan Avenue, Suite 900, Chicago, IL 60611, USA
    J Acquir Immune Defic Syndr 54:85-92. 2010
    ..To determine the efficacy of patient-selected treatment partners on virologic and adherence outcomes during first-line antiretroviral therapy...
  20. ncbi request reprint Antiretroviral treatment: current approach and future prospects
    B O Taiwo
    Department of Medicine, Duke University Medical Centre, Durham, NC, USA
    Afr J Med Med Sci 35:1-11. 2006
    ..The search for a cure is led by ongoing research in novel concepts such as structured treatment intervention and immune-based therapy...
  21. ncbi request reprint Cost-effectiveness of screening for HIV
    Babafemi O Taiwo
    N Engl J Med 352:2137-9; author reply 2137-9. 2005